Life Science Investing Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
Life Science Investing Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
Life Science Investing Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
Life Science Investing Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
Life Science Investing Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
Life Science Investing Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
Life Science Investing Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Life Science Investing Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Life Science Investing Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
Life Science Investing Candel Therapeutics to Participate in Upcoming Investor Conferences in September
Allied Critical Metals Confirms Ultra High-Grade Tungsten Zone at Borralha with 18.0 m @ 0.85 % WO3 including 4.0 m @ 3.72 % WO3
Pinnacle Identifies Gold-Silver Mineralization at Historic La Dura Mine, Extending Mineralized Horizon to Almost 500 Metres
Silver Dollar Discovers New Mineralized Zone at the Nora Silver-Gold Project and Receives Drill Permit
